UV Spectroscopic Estimation of Brivaracetam in Bulk Drug and Formulations

Epilepsy is characterized by recurring, uncontrollable seizures and associated co-morbidities. Convulsion episodes are caused by aberrant brain activity that manifests as symptoms and indicators for a short time. A novel, uncomplicated, accurate, basic, exact, and reasonably priced ultraviolet (UV) spectrophotometric approach with an enhanced detection range was created for the current investigation. Following a review of the literature, we discovered that there was only one way for estimating brivaracetam, which motivated us to create further techniques utilizing a UV spectrophotometer. Brivaracetam's maximum absorbance was discovered at λmax 217 nm. With a correlation coefficient of 0.9997, brivaracetam was demonstrated to be linear using the UV spectroscopic technique over the concentration range of 10–50µg/ml.A statistical analysis of the process revealed results that fell within the acceptable bounds. Using the least squares approach, a linear regression equation with the following values was produced: Y = 0.0524 X + 0.0879. The process was demonstrated to be affordable and less time-consuming in relation to the results, as well as accurate, exact, reproducible, andeasytouse. The analytical approach was created and validated using all validation parameters in accordance with ICH guidelines (ICH Q2 (R1)) in order to satisfy requirements such as accuracy, precision, linearity, reproducibility, interday, precision, intraday precision, robustness, and the limit of detection and limit of quantitation being found to be within acceptable bounds. The analysis results were also statistically validated.